(Last)

(Street)

(City)

WARREN

FORM 4

(First)

NJ

(State)

30 TECHNOLOGY DRIVE

1. Title of Security (Instr. 3)

Common Stock

C/O AQUESTIVE THERAPEUTICS, INC.

(Middle)

07059

(Zip)

Table I - Non

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

	OMB APPROVAL											
	OMB Number:	3235-0287										
	Estimated average burden											
- 1	hours nor roomanas	. 0.5										

Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 193 or Section 30(h) of the Investment Company Act of 1940						
1. Name and Address of Reporting Person*  Wargacki Stephen	2. Issuer Name <b>and</b> Ticker or Trading Symbol Aquestive Therapeutics, Inc. [ AQST ]						

	2. Issuer Name and Ticker or Trading Symbol Aquestive Therapeutics, Inc. [ AQST ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner					
	3. Date of Earliest Transaction (Month/Day/Year)     05/10/2024      4. If Amendment, Date of Original Filed (Month/Day/Year)							Officer (give title below)  Chief Scientific		Other (specify below)			
								6. Individual or Joint/Group Filing (Check Applicable Line)					
							X	Form filed by One Reporting Person					
								Form filed by More than One Reporting Person					
	Rule	e 10b5-1(c)	Tran	sact	ion Indica	-							
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
Derivative Securities Acquired, Disposed of, or Beneficially Owned													
2. Transact Date Month/Day		Execution Date, Transaction Disposed Of (D)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
			Code	v	Amount	(A) or	Price	Transaction(s)		(111501.4)			

 $10,000^{(1)}$ 

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

## **Explanation of Responses:**

1. The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

## Remarks:

/s/ Lori Braender, as Attorney-05/13/2024 In-Fact

\*\* Signature of Reporting Person Date

**\$0** 

267,963

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

05/10/2024

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.